Sign in or create an account to add this stock to your watchlist.
About Editas Medicine (NASDAQ:EDIT)
Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. It develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. The company also develops other therapies for eye diseases, such as Herpes Simplex Virus 1 that causes lifelong infections primarily leading to ocular and oral disease; and Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss. In addition, it develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited for the research and development of medicines for ocular diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EDIT
CUSIPN/A
Phone617-401-9000
Debt
Debt-to-Equity Ratio0.13
Current Ratio11.71
Quick Ratio11.71
Price-To-Earnings
Trailing P/E Ratio-12.26
Forward P/E Ratio-12.18
P/E GrowthN/A
Sales & Book Value
Annual Sales$13.73 million
Price / Sales125.58
Cash FlowN/A
Price / CashN/A
Book Value$5.24 per share
Price / Book6.97
Profitability
EPS (Most Recent Fiscal Year)($2.98)
Net Income$-120,320,000.00
Net Margins-707.98%
Return on Equity-58.73%
Return on Assets-32.36%
Miscellaneous
Employees112
Outstanding Shares47,200,000
Editas Medicine (NASDAQ:EDIT) Frequently Asked Questions
What is Editas Medicine's stock symbol?
Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."
How were Editas Medicine's earnings last quarter?
Editas Medicine (NASDAQ:EDIT) issued its quarterly earnings data on Thursday, May, 3rd. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.15. The firm had revenue of $3.90 million for the quarter, compared to analyst estimates of $4.04 million. Editas Medicine had a negative net margin of 707.98% and a negative return on equity of 58.73%. Editas Medicine's revenue was up 473.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.85) EPS. View Editas Medicine's Earnings History.
When is Editas Medicine's next earnings date?
What price target have analysts set for EDIT?
10 brokerages have issued twelve-month target prices for Editas Medicine's stock. Their forecasts range from $27.00 to $67.00. On average, they expect Editas Medicine's stock price to reach $47.1667 in the next year. View Analyst Ratings for Editas Medicine.
What are Wall Street analysts saying about Editas Medicine stock?
Here are some recent quotes from research analysts about Editas Medicine stock:
- 1. According to Zacks Investment Research, "Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts. " (5/15/2018)
- 2. Cann analysts commented, "Editas Medicine announced on February 16 the appointment of Jessica Hopfield, Ph.D., to its Board of Directors, effective immediately. Dr. Hopfield is currently the Chairperson of the Board of Trustees of the Joslin Diabetes Center and serves as Lead Independent Director on the Board of Directors of Insulet Corporation. We believe Dr. Hopfield will bring significant commercial and operational experience to the Editas board." (2/16/2018)
Who are some of Editas Medicine's key competitors?
Some companies that are related to Editas Medicine include Bio-Techne (TECH), CRISPR Therapeutics (CRSP), arGEN-X BV (ARGX), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), China Biologic Products (CBPO), Atara Biotherapeutics (ATRA), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Momenta Pharmaceuticals (MNTA), Repligen (RGEN), Acceleron Pharma (XLRN), Sangamo Therapeutics (SGMO), REGENXBIO (RGNX) and Iovance Biotherapeutics (IOVA).
Who are Editas Medicine's key executives?
Editas Medicine's management team includes the folowing people:
- Ms. Katrine S. Bosley, CEO, Pres & Director (Age 50)
- Dr. Charles Albright Ph.D., Chief Scientific Officer (Age 60)
- Dr. Gerald Cox M.D., Ph.D., Chief Medical Officer (Age 59)
- Dr. Feng Zhang Ph.D., Co-Founder and Scientific Advisory Board Member
- Dr. George M. Church Ph.D., Co-Founder and Scientific Advisory Board Member (Age 64)
When did Editas Medicine IPO?
(EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.
Has Editas Medicine been receiving favorable news coverage?
News articles about EDIT stock have been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Editas Medicine earned a news sentiment score of 0.13 on Accern's scale. They also gave media coverage about the company an impact score of 45.30 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Editas Medicine's major shareholders?
Editas Medicine's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.07%), Global Thematic Partners LLC (1.00%), Northern Trust Corp (0.89%), Millennium Management LLC (0.66%), Federated Investors Inc. PA (0.54%) and UBS Group AG (0.45%). Company insiders that own Editas Medicine stock include Alexandra Glucksmann, Andrew A F Hack, Boris Nikolic, Charles Albright, Gerald Frank Cox, Jessica Hopfield, Katrine Bosley, Kevin Bitterman, Kevin P Starr and Polaris Venture Management Co. View Institutional Ownership Trends for Editas Medicine.
Which major investors are selling Editas Medicine stock?
EDIT stock was sold by a variety of institutional investors in the last quarter, including Global Thematic Partners LLC, Millennium Management LLC, American Century Companies Inc., Commonwealth Equity Services LLC, Artal Group S.A., Guggenheim Capital LLC, Cim Investment Mangement Inc. and M&T Bank Corp. Company insiders that have sold Editas Medicine company stock in the last year include Andrew A F Hack, Charles Albright and Katrine Bosley. View Insider Buying and Selling for Editas Medicine.
Which major investors are buying Editas Medicine stock?
EDIT stock was acquired by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, BlackRock Inc., Elmwood Wealth Management Inc., UBS Group AG, Trexquant Investment LP, Northern Trust Corp, Schwab Charles Investment Management Inc. and Great West Life Assurance Co. Can. Company insiders that have bought Editas Medicine stock in the last two years include Boris Nikolic, Gerald Frank Cox and Jessica Hopfield. View Insider Buying and Selling for Editas Medicine.
How do I buy shares of Editas Medicine?
Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Editas Medicine's stock price today?
One share of EDIT stock can currently be purchased for approximately $36.53.
How big of a company is Editas Medicine?
Editas Medicine has a market capitalization of $1.70 billion and generates $13.73 million in revenue each year. The company earns $-120,320,000.00 in net income (profit) each year or ($2.98) on an earnings per share basis. Editas Medicine employs 112 workers across the globe.
How can I contact Editas Medicine?
Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected]
MarketBeat Community Rating for Editas Medicine (EDIT)
MarketBeat's community ratings are surveys of what our community members think about Editas Medicine and other stocks. Vote "Outperform" if you believe EDIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EDIT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Editas Medicine (NASDAQ:EDIT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
10 Wall Street analysts have issued ratings and price targets for Editas Medicine in the last 12 months. Their average twelve-month price target is $47.1667, suggesting that the stock has a possible upside of 29.12%. The high price target for EDIT is $67.00 and the low price target for EDIT is $27.00. There are currently 1 sell rating, 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.40 | 2.33 | 2.33 | 2.44 |
| Ratings Breakdown: | 1 Sell Rating(s)
4 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $47.1667 | $45.60 | $32.00 | $27.00 |
| Price Target Upside: | 29.12% upside | 10.21% upside | 8.02% downside | 17.04% upside |
Editas Medicine (NASDAQ:EDIT) Consensus Price Target History
Editas Medicine (NASDAQ:EDIT) Analyst Ratings History
Show:
(Data available from 5/26/2016 forward)
Editas Medicine (NASDAQ:EDIT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Editas Medicine (NASDAQ EDIT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.20%
Institutional Ownership Percentage: 65.36%
Editas Medicine (NASDAQ EDIT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/23/2018 | Charles Albright | Insider | Sell | 10,000 | $35.00 | $350,000.00 | 10,000 |  |
| 5/17/2018 | Jessica Hopfield | Director | Buy | 6,700 | $37.28 | $249,776.00 | 10,000 | |
| 5/1/2018 | Katrine Bosley | Insider | Sell | 8,333 | $31.95 | $266,239.35 | 1,301,965 | |
| 4/2/2018 | Katrine Bosley | Insider | Sell | 8,333 | $32.16 | $267,989.28 | | |
| 3/20/2018 | Andrew A F Hack | CFO | Sell | 40,000 | $38.06 | $1,522,400.00 | 6,000 | |
| 3/16/2018 | Andrew A F Hack | CFO | Sell | 6,000 | $39.43 | $236,580.00 | 6,000 | |
| 3/9/2018 | Katrine Bosley | Insider | Sell | 9,134 | $45.00 | $411,030.00 | 1,318,631 | |
| 3/1/2018 | Katrine Bosley | Insider | Sell | 8,333 | $35.72 | $297,654.76 | | |
| 2/16/2018 | Andrew A F Hack | CFO | Sell | 18,000 | $34.21 | $615,780.00 | | |
| 2/1/2018 | Katrine Bosley | CEO | Sell | 8,333 | $36.18 | $301,487.94 | 1,338,898 | |
| 1/30/2018 | Katrine Bosley | Insider | Sell | 20,000 | $38.79 | $775,800.00 | 1,354,431 | |
| 1/23/2018 | Katrine Bosley | Insider | Sell | 3,338 | $35.28 | $117,764.64 | 1,364,431 | |
| 1/3/2018 | Katrine Bosley | Insider | Sell | 14,995 | $34.15 | $512,079.25 | | |
| 12/19/2017 | Andrew A F Hack | CFO | Sell | 14,649 | $24.68 | $361,537.32 | 5,000 | |
| 12/15/2017 | Andrew A F Hack | CFO | Sell | 5,000 | $24.31 | $121,550.00 | 5,000 | |
| 12/1/2017 | Katrine Bosley | Insider | Sell | 8,333 | $29.58 | $246,490.14 | 1,387,897 | |
| 11/20/2017 | Andrew A F Hack | CFO | Sell | 5,000 | $25.35 | $126,750.00 | 5,000 | |
| 11/17/2017 | Andrew A F Hack | CFO | Sell | 5,000 | $24.81 | $124,050.00 | 5,000 | |
| 11/1/2017 | Katrine Bosley | Insider | Sell | 8,333 | $23.64 | $196,992.12 | 1,393,322 | |
| 10/2/2017 | Katrine Bosley | Insider | Sell | 8,333 | $24.78 | $206,491.74 | | |
| 9/5/2017 | Katrine Bosley | Insider | Sell | 16,666 | $20.33 | $338,819.78 | 1,414,629 | |
| 9/1/2017 | Katrine Bosley | CEO | Sell | 10,000 | $20.42 | $204,200.00 | 1,414,629 | |
| 8/11/2017 | Katrine Bosley | Insider | Sell | 16,666 | $20.02 | $333,653.32 | 1,431,095 | |
| 6/2/2017 | Boris Nikolic | Director | Buy | 35,000 | $14.07 | $492,450.00 | 35,000 | |
| 6/2/2017 | Gerald Frank Cox | Insider | Buy | 4,000 | $14.15 | $56,600.00 | 4,000 | |
| 5/22/2017 | Kevin Bitterman | Director | Sell | 1,000,000 | $17.00 | $17,000,000.00 | | |
| 3/15/2017 | Alexandra Glucksmann | COO | Sell | 1,000 | $26.41 | $26,410.00 | 118,788 | |
| 2/15/2017 | Alexandra Glucksmann | COO | Sell | 6,000 | $20.58 | $123,480.00 | 123,788 | |
| 2/15/2017 | Andrew A F Hack | CFO | Sell | 3,000 | $19.20 | $57,600.00 | 3,000 | |
| 1/11/2017 | Andrew A F Hack | CFO | Sell | 15,000 | $19.20 | $288,000.00 | 15,000 | |
| 12/7/2016 | Polaris Venture Management Co. | Major Shareholder | Sell | 75,000 | $15.82 | $1,186,500.00 | | |
| 12/6/2016 | Kevin Bitterman | Director | Sell | 130,000 | $15.79 | $2,052,700.00 | | |
| 11/23/2016 | Kevin Bitterman | Director | Sell | 21,480 | $15.71 | $337,450.80 | | |
| 11/22/2016 | Polaris Venture Management Co. | Major Shareholder | Sell | 12,819 | $15.77 | $202,155.63 | | |
| 11/15/2016 | Kevin Bitterman | Director | Sell | 88,900 | $16.96 | $1,507,744.00 | | |
| 9/8/2016 | Polaris Venture Management Co. | Major Shareholder | Sell | 500,000 | $16.80 | $8,400,000.00 | | |
| 9/6/2016 | Kevin P. Starr | Major Shareholder | Sell | 5,890 | $15.90 | $93,651.00 | | |
| 8/23/2016 | Alexandra Glucksmann | COO | Sell | 1,000 | $20.00 | $20,000.00 | 118,788 | |
| 2/8/2016 | James E Flynn | Insider | Buy | 100,000 | $16.00 | $1,600,000.00 | | |
(Data available from 1/1/2013 forward)
Editas Medicine (NASDAQ EDIT) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Editas Medicine (EDIT) Insider Charles Albright Sells 10,000 Shares
www.americanbankingnews.com - May 25 at 7:38 PM |
| -$0.69 Earnings Per Share Expected for Editas Medicine (EDIT) This Quarter
www.americanbankingnews.com - May 25 at 11:19 AM |
 | Rounds Report: Aimmune Is Gaining Momentum While Editas Experiences Significant Insider Purchases
seekingalpha.com - May 24 at 8:22 AM |
| Adverum: Assessing The Strong Prospects Of A Gene Therapy Innovator
seekingalpha.com - May 23 at 8:01 AM |
| Editas Medicine (EDIT) Director Buys $249,776.00 in Stock
www.americanbankingnews.com - May 21 at 7:52 PM |
 | BRIEF-Editas Medicine Reports Data Demonstrating Subretinal Injection Of Edit-101 Well-Tolerated In Non-Human ...
www.reuters.com - May 18 at 5:34 PM |
| BidaskClub Upgrades Editas Medicine (EDIT) to Buy
www.americanbankingnews.com - May 18 at 5:13 PM |
| Editas Medicine (EDIT) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - May 15 at 9:18 PM |
 | Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?
finance.yahoo.com - May 15 at 5:31 PM |
| Editas Medicine (EDIT) PT Lowered to $55.00
www.americanbankingnews.com - May 15 at 1:19 PM |
| [$$] Gene-Editing Pioneers Back Beam Therapeutics
finance.yahoo.com - May 14 at 9:35 AM |
| Reviewing Editas Medicine (EDIT) & Adaptimmune Therapeutics (ADAP)
www.americanbankingnews.com - May 14 at 5:33 AM |
| Your Guide to Investing in Gene Editing
finance.yahoo.com - May 12 at 8:33 AM |
| $6.20 Million in Sales Expected for Editas Medicine (EDIT) This Quarter
www.americanbankingnews.com - May 10 at 4:50 AM |
| Editas Medicine to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
finance.yahoo.com - May 8 at 8:22 AM |
| Editas Medicine (EDIT) Expected to Post Earnings of -$0.80 Per Share
www.americanbankingnews.com - May 8 at 5:18 AM |
| Editas Medicine (EDIT) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 8 at 1:48 AM |
| Editas Medicine (EDIT) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - May 7 at 2:51 AM |
 | Editas Medicine Starts a "Transformative" Year on a High Note
www.fool.com - May 5 at 11:13 AM |
 | Noteworthy Friday Option Activity: EDIT, TROX, GPRO
www.nasdaq.com - May 4 at 5:37 PM |
| Editas Medicine's (EDIT) CEO Katrine Bosley on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 4 at 8:11 AM |
| Edited Transcript of EDIT earnings conference call or presentation 3-May-18 9:00pm GMT
finance.yahoo.com - May 4 at 8:11 AM |
| Editas: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 8:11 AM |
| Editas Medicine (EDIT) Issues Quarterly Earnings Results, Beats Estimates By $0.15 EPS
www.americanbankingnews.com - May 3 at 9:05 PM |
| Katrine Bosley Sells 8,333 Shares of Editas Medicine (EDIT) Stock
www.americanbankingnews.com - May 3 at 8:14 PM |
| BRIEF-Editas Medicine Reports Q1 Loss Per Share Of $0.67
www.reuters.com - May 3 at 5:31 PM |
 | This Court Battle Will Decide Who Will Make a Fortune From Gene-Editing Tech
www.msn.com - May 2 at 8:04 AM |
| Top Gene-Editing Stocks for Long-Term Investors
finance.yahoo.com - May 1 at 5:31 PM |
 | Pre-Market Technical Scan on Biotech Equities -- Diffusion Pharma, Dynavax Technologies, Edge Therapeutics, and ...
www.prnewswire.com - May 1 at 8:00 AM |
 | Berkeley Fights Harvard, MIT Over Profits From Gene-Editing Tech
www.bloomberg.com - April 30 at 9:32 AM |
 | Form DEFA14A Editas Medicine, Inc.
www.streetinsider.com - April 28 at 5:28 PM |
| Editas Medicine to Host Conference Call Discussing First Quarter 2018 Corporate Update and Results
finance.yahoo.com - April 26 at 5:27 PM |
| Editas Medicine (EDIT) Downgraded by BidaskClub to Hold
www.americanbankingnews.com - April 26 at 1:32 PM |
 | Editas, Millennium vet launches new biotech with $56M from Third Rock
www.bizjournals.com - April 24 at 8:05 AM |
| Editas Medicine Inc (NASDAQ:EDIT): What Does The Future Look Like?
finance.yahoo.com - April 24 at 8:05 AM |
| $3.23 Million in Sales Expected for Editas Medicine (EDIT) This Quarter
www.americanbankingnews.com - April 23 at 5:33 AM |
| NanoString Technologies (NSTG) vs. Editas Medicine (EDIT) Financial Comparison
www.americanbankingnews.com - April 23 at 1:50 AM |
| Zacks: Brokerages Anticipate Editas Medicine (EDIT) Will Announce Earnings of -$0.77 Per Share
www.americanbankingnews.com - April 21 at 1:20 AM |
| Editas Medicine (EDIT) Given "Market Perform" Rating by Oppenheimer Analysts
www.americanbankingnews.com - April 17 at 7:01 PM |
| BidaskClub Upgrades Editas Medicine (EDIT) to "Buy"
www.americanbankingnews.com - April 13 at 11:05 AM |
| Editas Medicine (EDIT) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 13 at 1:40 AM |
| Editas Medicine (EDIT) Given "Hold" Rating at Cann
www.americanbankingnews.com - April 11 at 6:13 PM |
| JPMorgan Chase Reiterates "$27.00" Price Target for Editas Medicine (EDIT)
www.americanbankingnews.com - April 11 at 1:19 PM |
| Zacks Investment Research Downgrades Editas Medicine (EDIT) to Sell
www.americanbankingnews.com - April 7 at 3:53 PM |
| Brokerages Anticipate Editas Medicine Inc (EDIT) Will Post Quarterly Sales of $3.23 Million
www.americanbankingnews.com - April 6 at 4:43 AM |
| Editas Medicine (EDIT) Downgraded by ValuEngine
www.americanbankingnews.com - April 5 at 6:52 PM |
| Editas Medicine (EDIT) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - April 5 at 1:57 PM |
| Editas Medicine Inc (EDIT) Insider Katrine Bosley Sells 8,333 Shares
www.americanbankingnews.com - April 4 at 10:56 PM |
| Brokerages Anticipate Editas Medicine Inc (EDIT) Will Announce Earnings of -$0.77 Per Share
www.americanbankingnews.com - April 4 at 3:06 AM |
| Form 3 Editas Medicine, Inc. For: Mar 27 Filed by: MULLEN JAMES C
www.streetinsider.com - March 30 at 8:27 AM |
Editas Medicine (NASDAQ:EDIT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Editas Medicine (NASDAQ:EDIT) Income Statement, Balance Sheet and Cash Flow Statement
Editas Medicine (NASDAQ EDIT) Stock Chart for Saturday, May, 26, 2018
Loading chart…
